Publications by authors named "Daniela Bellarosa"

Claim this Profile
T
The Dual PIM/FLT3 Inhibitor MEN1703 Combines Synergistically With Gilteritinib in FLT3-ITD-Mutant Acute Myeloid Leukaemia.
Sonia Zicari, Giuseppe Merlino, Alessandro Paoli, Alessio Fiascarelli, Patrizia Tunici, Daniela Bellarosa

J Cell Mol Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer.
Alessio Fiascarelli, Giuseppe Merlino, Stefania Capano, Simone Talucci, Diego Bisignano, Daniela Bellarosa

Breast Cancer Res Treat· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia.
Yuliya Yakymiv, Stefania Augeri, Giulia Fissolo, Silvia Peola, Cristiano Bracci, Daniela Bellarosa

Cells· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors.
Giuseppe Merlino, Alessio Fiascarelli, Mario Bigioni, Alessandro Bressan, Corrado Carrisi, Daniela Bellarosa

Mol Cancer Ther· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAHA/Vorinostat induces the expression of the CD137 receptor/ligand system and enhances apoptosis mediated by soluble CD137 receptor in a human breast cancer cell line.
Daniela Bellarosa, Alessandro Bressan, Mario Bigioni, Massimo Parlani, Carlo Alberto Maggi

Int J Oncol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Induction of a less aggressive phenotype in human colon carcinoma HCT116 cells by chronic exposure to HDAC inhibitor SAHA.
Alessandro Bressan, Mario Bigioni, Daniela Bellarosa, Federica Nardelli, Clelia Irrissuto

Oncol Rep· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor activity of delimotecan against human metastatic melanoma: pharmacokinetics and molecular determinants.
Mario Bigioni, Massimo Parlani, Alessandro Bressan, Daniela Bellarosa, Licia Rivoltini

Int J Cancer· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sabarubicin (MEN10755)-induced apoptosis is independent from mtDNA in A2780 human ovarian tumor cells.
Alessandro Bressan, Federica Nardelli, Daniela Bellarosa, Mario Bigioni, Giuseppe Curcurù

Anticancer Res· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The synergistic interaction of interferon types I and II leads to marked reduction in severe acute respiratory syndrome-associated coronavirus replication and increase in the expression of mRNAs for interferon-induced proteins.
Carolina Scagnolari, Simona Trombetti, Alessia Alberelli, Simona Cicetti, Daniela Bellarosa

Intervirology· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human and murine macrophages mediate activation of MEN 4901/T-0128: a new promising camptothecin analogue-polysaccharide conjugate.
Monica Binaschi, Massimo Parlani, Daniela Bellarosa, Mario Bigioni, Carmela Salvatore

Anticancer Drugs· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sabarubicin- (MEN 10755) and paclitaxel show different kinetics in nuclear factor-kappaB (NF-kB) activation: effect of parthenolide on their cytotoxicity.
Daniela Bellarosa, Monica Binaschi, Carlo Alberto Maggi, Cristina Goso

Anticancer Res· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis